Bristol Myers Squibb (BMY)财务
NYSE · Healthcare · Drug Manufacturers - General · 员工32,500人 · CEO Christopher Boerner
- 股价
- $62.48 +1.78%
- 市值
- $1280亿
- 企业价值
- $1630亿
- 最近财报
- Q3 '26 2026-10-29提交
- 下次财报
- 2027-02-04 EPS预期 $1.52
营收(TTM)$500亿+4.2% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)26.1%+2.3 百分点 对比去年同期营业利润 $130亿
净利润(TTM)$92.4亿+53.1% 对比去年同期税后,含营业外收益
自由现金流(TTM)$92.9亿-39.3% 对比去年同期资本支出 $13.7亿
稀释EPS(TTM)$4.51+52.6% 对比去年同期最近4个季度之和
净现金-$322亿+6.7% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $1280亿 EV $1630亿
- 营收
- $500亿 过去12个月
- 营收增速
- +4% FY2026年一致预期
- 净利润率
- 18.5% 净利润 / 营收,TTM
- P/E
- 13.8× 预期 9.7×(FY2026)
- P/S
- 2.6× 股价 / 营收,TTM
- EV / EBITDA
- 10.8× TTM
- 自由现金流
- $92.9亿 过去12个月
- 净利润
- $92.4亿 过去12个月
- 营收预期
- $501亿 FY2026年一致预期
- 盈利
- 2027-02-04 营收预期 $127亿
- 股息
- $2.52 每股,过去12个月
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-29):营收超预期2.7%,EPS 超预期22.7%营收$131亿,预期$127亿(+2.7%);EPS $1.35,预期$1.10(+22.7%)。
- 营收增长加速:同比6.9%Q3 '26营收$131亿,此前四个季度的平均值为3.1%。
- 营业利润率26.1%(TTM),较去年同期+2.3 百分点营收增长4.2%,营业利润增长14.2%。
- 税前利润的15.1%被营业外亏损吞噬税前利润$113亿,营业利润$130亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 资本支出占营收的2.7%(去年为2.7%)最近4个季度投入$13.7亿(同比+3.6%)。自由现金流$92.9亿,相当于净利润的100.5%。
- 股东回报$52.2亿 = 自由现金流的56.2%回购$9800万(去年为$0),股息$51.2亿,股权激励$5.52亿(TTM)。
- 稀释股数一年内增加0.7%Q3 '26稀释股数20.5亿,一年前为20.4亿。
- 净债务 $322亿现金 + 短期投资 $126亿,含租赁债务 $448亿;一年前净债务 $345亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $131亿 | $122亿 | +6.9% |
| 毛利率 | 68.3% | 71.9% | -3.6 百分点 |
| 营业利润 | $28.4亿 | $36.4亿 | -21.9% |
| 营业利润率 | 21.8% | 29.8% | -8.0 百分点 |
| 净利润 | $21.6亿 | $22亿 | -1.8% |
| 稀释EPS | $1.05 | $1.08 | -2.8% |
| 经营现金流 | $41.8亿 | $63.1亿 | -33.8% |
| 资本支出 | $3.44亿 | $3.2亿 | +7.5% |
| 自由现金流 | $38.4亿 | $59.9亿 | -36.0% |
| R&D | $23.7亿 | $25.3亿 | -6.4% |
| 股权激励费用 | $1.38亿 | $1.39亿 | -0.7% |
实际 vs 一致预期
2026-10-29| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $131亿 | $127亿 | +2.7% |
| EPS(一致预期口径) | $1.35 | $1.10 | +22.7% |
来自2026-10-29发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Eliquis | $46.9亿 | +25.2% | 35.9% | $168亿 | +18.1% | |
| Opdivo | $23.7亿 | -6.2% | 18.2% | $97亿 | -1.4% | |
| Revlimid | $3.03亿 | -47.3% | 2.3% | $16.8亿 | -54.5% | |
| Orencia | $9.83亿 | +2.0% | 7.5% | $38.4亿 | +3.9% | |
| Pomalyst/Imnovid | $1.3亿 | -80.7% | 1.0% | $15.4亿 | -46.3% | |
| Yervoy | $7.93亿 | +7.3% | 6.1% | $30.2亿 | +9.3% | |
| Reblozyl | $7.5亿 | +22.0% | 5.7% | $27.1亿 | +22.6% | |
| Other Growth Brands | $7.31亿 | +42.2% | 5.6% | $25亿 | +31.8% | |
| Sprycel | $7300万 | -38.7% | 0.6% | $3.13亿 | -48.9% | |
| Breyanzi | $5.26亿 | +46.5% | 4.0% | $18.1亿 | +47.5% | |
| Camzyos | $4.2亿 | +41.9% | 3.2% | $15亿 | +60.2% | |
| Opdualag | $3.67亿 | +22.7% | 2.8% | $13.6亿 | +25.0% | |
| Opdivo Ovantig | $3.34亿 | +398.5% | 2.6% | $8.9亿 | – | |
| Abraxane | $6500万 | -12.2% | 0.5% | $2.54亿 | -44.5% | |
| Other Legacy Brands | $1.54亿 | -13.0% | 1.2% | $6.79亿 | -20.0% | |
| Zeposia | $1.68亿 | +4.3% | 1.3% | $6.14亿 | +6.6% | |
| Abecma | – | – | – | – | – | |
| Sotyktu | $1亿 | +25.0% | 0.8% | $3.42亿 | +18.8% | |
| Cobenfy | $5700万 | +32.6% | 0.4% | $2.26亿 | – | |
| Krazati | $5800万 | +9.4% | 0.4% | $2.19亿 | +16.5% |
按地区划分的营收
占总额比例| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $90.7亿 | +8.9% | 95.7% | $344亿 | +3.3% | |
| Other Region | $4.03亿 | +39.0% | 4.3% | $12.9亿 | +14.1% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $107亿
- 资本支出
- -$13.7亿
- 股票回购
- -$9800万
- 股息
- -$51.2亿
- 收购
- -$27亿
- 债务净发行
- -$62.6亿
- 股权激励费用
- $5.52亿
- 自由现金流
- $92.9亿
- 股东回报 / FCF
- 56.2%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 13.8× | 18.2× 5年中的4年 | 13.2× – 24.2× |
| EV / EBITDA | 10.8× | 16.8× | 7.0× – 49.1× |
| EV / 营收 | 3.3× | 3.4× | 3.0× – 4.0× |
| 股价 / FCF | 13.8× | 9.4× | 8.2× – 12.8× |
| 股价 / 净资产 | 5.5× | 5.1× | 3.6× – 7.0× |
| FCF收益率 | 7.3% | 10.9% | 7.8% – 12.2% |
| 投入资本回报率 | 14.9% | 10.2% | 8.0% – 15.0% |
| 净资产收益率 | 43.9% | 10.1% | -54.8% – 38.2% |
分析师
一致目标价 $66.08 (+5.8%)
区间 $41.00 – $78.00 · 评级 Hold
强烈买入0
买入19
持有21
卖出2
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $501亿 | +3.9% | $6.42 | +86.1% | 9.7× | 16 |
| FY2027 | $487亿 | -2.7% | $6.65 | +3.6% | 9.4× | 15 |
| FY2028 | $406亿 | -16.6% | $5.33 | -20.0% | 11.7× | 8 |
| FY2029 | $374亿 | -8.0% | $4.86 | -8.7% | 12.9× | 5 |
| FY2030 | $371亿 | -0.6% | $4.92 | +1.3% | 12.7× | 5 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Bristol-Myers Squibb Company在近期10-Q / 10-K文件中标记的全部326项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent | $1500万2025-12-31 | $4.52亿 | -96.7% | $1500万 | $4.52亿 | -96.7% |
| Accounts and Other Receivables, Net, Current | $14.5亿 | – | – | – | – | – |
| Accounts Payable, Current | $46.3亿 | $42.9亿 | +7.9% | $35.8亿 | $36亿 | -0.7% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $91.9亿 | $96.2亿 | -4.5% | $95.9亿 | $90.1亿 | +6.4% |
| Accounts Receivable, Allowance for Credit Loss, Current | $6000万 | $5200万 | +15.4% | $5800万 | $4500万 | +28.9% |
| Accounts Receivable, before Allowance for Credit Loss, Current | $100亿 | $107亿 | -5.9% | $114亿 | $99.6亿 | +14.2% |
| Accrued Income Taxes, Current | $7.27亿 | $10.2亿 | -28.9% | $9.79亿 | $15.1亿 | -35.3% |
| Accrued Income Taxes, Noncurrent | $9亿 | $17.4亿 | -48.2% | $14.1亿 | $14.9亿 | -5.6% |
| Accrued Liabilities | $6400万 | $6000万 | +6.7% | $6100万 | $6600万 | -7.6% |
| Accrued Royalties, Current | $5.65亿 | $5.13亿 | +10.1% | $5.37亿 | $4.77亿 | +12.6% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $56.9亿 | $52亿 | +9.5% | $52.9亿 | $49.5亿 | +7.0% |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax | $5.59亿 | $6.26亿 | -10.7% | $5.66亿 | $6.48亿 | -12.7% |
| Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | -$8.37亿 | -$8.72亿 | +4.0% | -$9.97亿 | -$9.68亿 | -3.0% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$12.8亿 | -$15.1亿 | +15.3% | -$15.2亿 | -$12.4亿 | -23.1% |
| Additional Paid in Capital | $467亿 | $463亿 | +0.9% | $464亿 | $460亿 | +0.8% |
| Amortization of Intangible Assets | $4.91亿 | $8.67亿 | -43.4% | $35亿 | $90亿 | -61.1% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | 2100万 | -100.0% | 0 | 3800万 | -100.0% |
| AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax | $1.2亿 | -$1800万 | +766.7% | $3700万 | $3.76亿 | -90.2% |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | -$600万 | $300万 | -300.0% | $300万 | $200万 | +50.0% |
| Assets | $888亿 | $969亿 | -8.4% | $900亿 | $926亿 | -2.8% |
| Assets for Plan Benefits, Defined Benefit Plan | $3.35亿 | $2.81亿 | +19.2% | $3.3亿 | $2.34亿 | +41.0% |
| Assets, Current | $298亿 | $356亿 | -16.5% | $294亿 | $298亿 | -1.3% |
| Buildings and Improvements, Gross | $79.7亿 | $71.2亿 | +11.9% | $72.7亿 | $65.8亿 | +10.5% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $0 | $0 | – | $3.51亿 | $0 | – |
| Business Combination, Integration Related Costs | $1000万 | $3600万 | -72.2% | $1.47亿 | $2.84亿 | -48.2% |
| Cash and Cash Equivalents, at Carrying Value | $95.7亿 | $157亿 | -39.1% | $102亿 | $103亿 | -1.3% |
| Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months | $700万 | -$2600万 | +126.9% | $7200万 | $1.86亿 | -61.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $95.7亿 | $157亿 | -39.1% | $102亿 | $103亿 | -1.2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $8.52亿 | $31.2亿 | -72.6% | -$1.29亿 | -$11.7亿 | +89.0% |
| Common Stock, Dividends, Per Share, Declared | $0.63 | $0.62 | +1.6% | $2.49 | $2.42 | +2.9% |
| Common Stock, Par or Stated Value Per Share | $0.102025-12-31 | $0.10 | 0.0% | $0.10 | $0.10 | 0.0% |
| Common Stock, Shares Authorized | 45亿2025-12-31 | 45亿 | 0.0% | 45亿 | 45亿 | 0.0% |
| Common Stock, Shares, Issued | 29亿2025-12-31 | 29亿 | 0.0% | 29亿 | 29亿 | 0.0% |
| Common Stock, Value, Outstanding | $2.92亿 | $2.92亿 | 0.0% | $2.92亿 | $2.92亿 | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $0 | -$600万 | +100.0% | $200万 | $1500万 | -86.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $21.7亿 | $22.4亿 | -3.2% | $67.7亿 | -$86.4亿 | +178.3% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $21.7亿 | $22.4亿 | -2.9% | $67.7亿 | -$86.3亿 | +178.5% |
| Construction in Progress, Gross | $14.8亿 | $14.6亿 | +1.9% | $16.2亿 | $15.3亿 | +6.2% |
| Contract with Customer, Asset, after Allowance for Credit Loss, Current | $8500万 | $2.24亿 | -62.1% | $1.92亿 | $3.85亿 | -50.1% |
| Contract with Customer, Performance Obligation Satisfied in Previous Period | $4.69亿 | $3.18亿 | +47.5% | $13亿 | $7.97亿 | +63.1% |
| Contractual Obligation | – | – | – | $64亿2021-06-30 | – | – |
| Cost of Goods and Services Sold | $41.5亿 | $34.4亿 | +20.7% | $139亿 | $140亿 | -0.2% |
| Costs and Expenses | $105亿 | $91.1亿 | +15.6% | $389亿 | $567亿 | -31.4% |
| Current Federal Tax Expense (Benefit) | – | – | – | $17亿 | $12.8亿 | +32.8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $15.4亿 | $13.6亿 | +12.8% |
| Current Income Tax Expense (Benefit) | – | – | – | $32.4亿 | $26.4亿 | +22.5% |
| Debt Instrument, Face Amount | $424亿 | $482亿 | -12.1% | $443亿 | $489亿 | -9.4% |
| Debt Instrument, Fair Value Disclosure | $360亿 | $458亿 | -21.4% | $415亿 | $453亿 | -8.4% |
| Debt Instrument, Unamortized Discount | $3.3亿 | $3.67亿 | -10.1% | $3.47亿 | $3.9亿 | -11.0% |
| Debt Instrument, Unamortized Premium | $7.25亿 | $7.87亿 | -7.9% | $7.51亿 | $8.23亿 | -8.7% |
| Debt Securities, Available-for-sale, Current | $30.1亿 | $7.76亿 | +287.5% | $4.64亿 | $5.13亿 | -9.6% |
| Debt Securities, Available-for-sale, Noncurrent | $3.78亿 | $4.06亿 | -6.9% | $3.96亿 | $3.2亿 | +23.8% |
| Debt, Current | $10.3亿 | $45.1亿 | -77.2% | $22.6亿 | $20.5亿 | +10.5% |
| DebtInstrumentRepaidPrincipal | $0 | – | – | – | – | – |
| Deferred Compensation Liability, Classified, Noncurrent | $5.14亿 | $4.87亿 | +5.5% | $4.87亿 | $4.56亿 | +6.8% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$11.1亿 | -$21.9亿 | +49.3% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $1.42亿 | $9600万 | +47.9% |
| Deferred Income Tax Assets, Net | $58.8亿 | $49.6亿 | +18.6% | $53.8亿 | $42.4亿 | +27.0% |
| Deferred Income Tax Expense (Benefit) | -$5.1亿 | -$3.59亿 | -42.1% | -$9.65亿 | -$20.9亿 | +53.8% |
| Deferred Income Tax Liabilities, Net | $2.28亿 | $2.25亿 | +1.3% | $2.22亿 | $3.69亿 | -39.8% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-01